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1. Introduction 
Cystic Fibrosis (CF) is a systemic disease impacting upon several organ systems. These include 
gastrointestinal, reproductive, endocrine and pulmonary manifestations of which the latter 
contributes the heaviest burden of disease morbidity, mortality and impact on quality of life. 
The defective protein in the disease state is the Cystic Fibrosis Transmembrane Regulator 
(CFTR) that normally functions as an ion channel permitting intracellular chloride escape. 
Regulated by cyclic adenosine monophosphate (cAMP) and localized to the apical membrane 
of epithelial cells, CFTR’s function is diminished or absent in CF precipitating a cycle of events 
including sodium hyper-absorption, mucus hypersecretion, impaired mucociliary clearance 
and pathogenic colonization with microorganisms. This in turn leads to the clinical picture of 
recurrent infections, bronchiectasis and airway destruction culminating in respiratory failure 
and premature death (Davis et al., 1996).  
Several hundred mutations of the CFTR gene have been described with a sub-group causing 
disease. Differing mutations impact upon CFTR channel expression, localization and activity 
and in some cases a combination of these important functions. Dependent on these factors, 
CFTR mutations have been stratified into six distinct classes for example the class II ∆F508 
mutation encodes a CFTR protein that is both defectively folded and processed resulting in 
disease (Rowe et al., 2005).  Whilst the Republic of Ireland has both the highest incidence 
and carrier rates of CF worldwide, ∆F508 accounts for >95% alleles identified (Farrell, 2008). 
An important long-standing observation in CF remains the fact that a gender dichotomy has 
been described. Females have poorer survival, worse lung function and earlier colonization 
with Pseudomonas aeruginosa when compared to males without adequate explanation. The 
following chapter will initially outline past epidemiological observations that have been 
made with regard to the CF ‘gender gap’ followed by our present understanding of 
potential explanations for these gender differences. A special focus on the major female sex 
hormone estrogen will be emphasized particularly its impact on the inflammatory and 
immune state within the female CF airway. Finally, directions for future basic science and 
clinical research in the area will be outlined. 
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2. Past observations  
The female gender disadvantage has been observed in CF morbidity and mortality and is 
reported throughout the early literature. Differences encompass survival, lung function, 
frequency of infections and microbiological variation however despite investigation 
explanations have remained elusive. With the lack of adequate explanation persisting over 
the last decade, controversy has emerged as to whether such disparities in fact ever existed 
and if such variation could be explained by therapeutic factors or treatment differences 
alone that exist between countries and care centers worldwide.  
The gender dichotomy outlined within early work in CF states that CF females have poorer 
survival, worse lung function and earlier colonization with P. aeruginosa. Early work by 
Corey et al (Corey & Farewell, 1996) assessing almost four thousand individuals with the 
disease from the Canadian registry illustrated that although regional differences in survival 
were identified that females had diminished survival of greater than five years when 
compared to males utilizing cohorts from both the 70’s and 80’s. The poorer survival in 
females was associated with poorer weight however the close inter-relation between 
declining pulmonary function, weight maintainence, gender and mortality was recognized 
and put forward for further investigation (Corey & Farewell, 1996). Similar results to these 
were uncovered from an Italian registry and then further confirmed in an independent 
United Kingdom assessment of mortality and survival in CF extending from 1947-2003 
(Bossi et al., 1999; Dodge et al., 2007).  In the early 90’s, an important demographic shift in 
CF survival was noted. CF patients who previously were not surviving past childhood were 
now progressing to young adults. The proportion of adults with CF increased fourfold 
between the 70’s and 90’s together with a doubling of median survival from 14 to 28 years of 
age. Such changes in the age distribution of CF survival at this time provided clinicians 
further insight into the natural history of the disease that was previously unknown. Despite 
these improvements to CF survival, female patients continued to show a lower median 
survival age compared to males (25 versus 30 years of age in 1990) (FitzSimmons, 1993).  
Subsequent study involving >20,000 patients with CF and utilizing Cox proportional 
hazards regression analysis to compare age-specific mortality rates between genders again 
confirmed gender differences in median CF survival (25.3 versus 28.4 years for females 
versus males respectively) (Rosenfeld et al., 1997). Additionally, this work aimed to identify 
particular risk factors that may serve as potential explanatory variables for the observed 
gender related survival differences (Rosenfeld et al., 1997). Despite analysis using a variety 
of risk factors for death in CF including poor nutritional status, lung function, airway 
microbiology, pancreatic insufficiency, age at diagnosis, mode of presentation and race, 
none could account for the gender disparity identified further confirming the existence of a 
genuine ‘gender gap’ (Rosenfeld et al., 1997). Consequential to this and other works, it was 
unsurprising to note that gender was included as a major parameter in a predictive 5-year 
CF survivorship model developed to help both researchers and clinicians evaluate therapies, 
improve prospective study design, monitor practice patterns, counsel individual patients 
and aid determination of suitable candidates for lung transplantation (Liou et al., 2001).   
A lack of explanation for such gender differences in CF disease together with a narrowing of 
this gap recently has ignited controversy with regard to whether the CF ‘gender gap’ ever 
existed. Some arguments have been put forward against the phenomena of the female 
disadvantage in CF which attempt to explain the gender differences based on therapeutic 
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advances occurring over the last decade in the management of the disease. For instance, 
retrospective cross sectional analysis of annual assessment data from a single center has 
shown that during childhood and adolescence, the lung function and nutrition of CF 
patients should be equal between the genders and that individual clinic practice should be 
reviewed if a gender gap persists. The authors argue that prior studies that have shown 
poorer prognosis in CF females have generally combined data from several centers and that 
their aim was to determine whether with modern aggressive treatment of CF this gender 
difference remains when care is standardized within a single center (Verma et al., 2005). 
Whilst some of the arguments put forward by this work may be plausible, an important 
point to consider remains that the gender differences observed in CF were most clearly 
observed post-puberty and during adulthood and not during the adolescent years, the 
group assessed by this work. To lend further argument to this, recent data from an Italian 
registry confirmed the absence of a gender gap in CF survival however this assessment only 
included patients up to 16 years of age, too early to identify the previously described gender 
dichotomy (Viviani et al., 2011). As a result, one of the conclusions drawn from this dataset 
was that the emergence of mortality differences between the genders could not be excluded 
if this cohort was to be followed into adulthood, the timeframe of interest in older studies 
(Viviani et al., 2011).  Additionally, although Olsen et al did acknowledge that females with 
CF are at higher risks of P. aeruginosa and Burkholderia colonization, require more intensified 
treatments with antibiotics and have greater rates of hospitalizations compared to males, 
they found no gender effect upon survival. It was again reiterated in the conclusions to this 
work that gender survival differences may in fact follow adolescence, the age group studied 
(Olesen et al., 2010).  
To overcome some of the weaknesses in comparing CF survival data between institutions, a 
case mix adjustment method may be employed (O’Connor et al., 2002). Such a method 
accounts for baseline differences in both patient and disease characteristics and although no 
consensus with regards its use in CF currently exists, the characteristics utilized for such an 
adjustment should include those that differ across institutions and are associated with 
patient survival. By accounting for characteristics of disease severity that may be a 
consequence of treatment effectiveness, this analysis can abolish the argument put forward 
that improvements to treatment account for gender discrepancies observed in CF disease. 
Using such case mix adjustment methodologies, O’Connor et al have shown that female 
gender in CF remains associated with an increased risk of death (O’Connor et al., 2002). This 
conclusion is reached using a model encompassing patient and disease characteristics that 
are present at the time of diagnosis and not influenced by subsequent treatment 
strengthening the argument for the existence of a true ‘gender gap’. 
An alternative argument put forward to refute a true ‘gender gap’ is greater compliance to 
therapy among female patients with CF. Masterson et al studied adherence to infection 
control guidelines and medical therapy in a CF cohort and found that although age-related 
differences exist, gender was importantly not a significant factor for treatment adherence 
(Masterson et al., 2010).  
In view of disagreement about the existence for gender variation in CF, a re-assessment for 
these differences was performed in early 2000, a time where survival rates were noted to 
have exponentially improved since the mid 80’s. Although survival of both genders was 
discovered to have benefitted from this trend, females had consistently poorer survival rates 
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compared to male patients re-iterating the existence of genuine gender differences (Kulich et 
al., 2003). This has been more recently confirmed by data published from our own Irish 
registry (Jackson et al., 2011).  As a consequence, it is clear that female gender is a negative 
prognostic factor in CF – a finding illustrated across several countries, registries and CF care 
centers.  
In addition to survival variances, differences in the acquisition and conversion of the major 
pathogen and colonizer P. aeruginosa have been described in CF. Females with CF acquire P. 
aeruginosa in advance of males and furthermore convert to their mucoid phenotype earlier 
conferring worse clinical outcomes (Demko et al., 1995). Longitudinal assessment of this 
organism in CF has shown a relatively short transition from no P. aeruginosa to non-mucoid 
P. aeruginosa however a much more prolonged period, sometimes over a decade preceding 
mucoid conversion. Transition to mucoid correlated with a deterioration in cough and chest 
radiography scores along with pulmonary function (Li et al., 2005).  
Interestingly, an assessment specifically designed to evaluate whether earlier acquisition of 
P. aeruginosa by females in CF, the greater impact of the organism on lung function or a 
combination of both factors contributed to the poorer survival in females found that 
although acquisition of mucoid organism was associated with an increased rate of decline of 
pulmonary function in both genders males had consistently better FEV1 (% predicted) and 
survival rates compared to females. This suggests that alternative factors and not P. 
aeruginosa alone contribute to the gender differences observed in female CF patients (Demko 
et al., 1995). Separate and independent analysis of the risk factors for initial acquisition of P. 
aeruginosa in children with CF identified by newborn screening found that female gender 
amongst others represents an important risk for early detection (Maselli et al., 2003).  
Further study has additionally shown that whilst chronic mucoid P. aeruginosa can have 
prognostic implications in disease outcomes, that female gender again remains an important 
risk factor for its early detection (Levy et al., 2008).  
Whilst these past observations illustrate that gender differences are an important 
consideration in CF disease, they importantly do not explain why they exist. One important 
difference between genders and a potential avenue for exploration is the circulating female 
hormone estrogen. Estrogens are the primary female sex hormone and have fundamental 
roles during the menstrual cycle. They circulate in three forms: estrone (E1), estradiol (E2) 
and estriol (E3), with E2 being the predominant and most active form in the non-pregnant 
state. Both E2 and progesterone fluctuations throughout the menstrual cycle have been 
implicated to impact upon pulmonary function however explanations to address such 
differences in CF remain lacking (Tam et al., 2011).  Our group and others have conducted 
studies examining E2 and its effects on infectious, inflammatory and immune consequences 
in the CF airway. Although such work remains ongoing, its results may provide insight for 
the first time into reasons for these fundamental gender differences that so far have not been 
adequately explained.    
2.1 Pulmonary innate immunity 
The lung constitutes a large surface of the body in contact with the outside environment. It 
is continuously exposed to a large number of airborne microbes or microbial molecules, and 
can also be confronted with pathogens approaching via the blood stream. A number of 
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factors including lung structure and physiology and components of the pulmonary innate 
immune system interact to contribute to effective pulmonary defenses. Individual key 
factors of pulmonary innate immunity will be outlined following which the effects that E2 
may have on each component will be discussed. These include, but are not limited to the 
following: 
2.1.1 Airway surface liquid (ASL)  
The ASL is a protective layer of fluid that covers the airway epithelium. It contains 
electrolytes, soluble proteins and importantly provides an interface within which cilia can 
beat and move mucus up through the respiratory tract. The mucociliary escalator together 
with pulmonary surfactant provides a barrier material at the air-liquid interface of the lungs. 
Surfactant contains the surfactant proteins A (SP-A), SP-B, SP-C and SP-D which help to 
lower the surface tension and participate in innate immune defence.  
2.1.2 Pattern recognition receptors (PRRs)  
Toll-like receptors (TLRs) comprise a major family of PRRs that fulfil key roles in 
recognising, discriminating and responding to microbial infection (Greene & McElvaney, 
2005). They are associated principally with macrophages and dendritic cells, however their 
expression is widespread and includes, but is not limited to cells of myeloid and lymphoid 
origin. TLRs are also expressed by pulmonary epithelial cells (Greene et al., 2005). 
Activation of TLRs by their cognate ligands can lead to induction of proinflammatory 
cytokine and antimicrobial peptide expression or up regulation of type 1 interferons. TLRs 
can also communicate with the adaptive immune response via modulation of cell adhesion 
and co-stimulatory molecules to induce longer term immunity and a range of non-microbial 
endogenous factors can also activate certain TLRs. 
2.1.3 Antimicrobial proteins  
A selection of antimicrobial peptides including the human beta-defensins (HBDs), 
cathelicidin/hCAP-18/LL-37, lactoferrin and lysozyme can be found in the respiratory tract. 
In addition to their direct bacterial killing activity some of these proteins also have anti-
biofilm, anti-inflammatory and anti-viral properties (Rogan et al., 2006).  
2.1.4 Proteases  
In the healthy lung proteases fulfil basic homeostatic roles and regulate processes such as 
regeneration and repair. The principal classes of protease present in the lung are the serine, 
cysteinyl, aspartyl and metalloproteases. These can function to regulate processes as diverse 
as tissue remodelling, mucin expression, neutrophil chemotaxis and bacterial killing. 
Members of these protease classes orchestrate a diverse range of changes with respect to 
infection and inflammation in the lung (Greene & McElvaney, 2009).  
2.1.5 Antiprotease protection in the lung  
The activity of pulmonary proteases is regulated by antiproteases. There are three major 
serine antiproteases in the lung – alpha-1 antitrypsin, secretory leucoprotease inhibitor 
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(SLPI) and elafin. In addition to their anti-protease activities they also possess other intrinsic 
immunomodulatory, anti-inflammatory and antimicrobial properties (Greene & McElvaney, 
2009).  
2.2 Dysfunctional pulmonary innate immunity in cystic fibrosis  
Pulmonary infection and inflammation in the CF lung are multifaceted processes. Defective 
chloride ion conductance due to mutant CFTR causes a decrease in the height of the ASL 
and an increase in both the volume and viscosity of mucus. The most important airway 
mucins are the secreted mucins, Muc5AC and Muc5B which are produced by goblet cells of 
the superficial airway epithelium. Their expression is increased in the CF lung and the 
overall composition of CF mucus is altered due to an increased content of macromolecules 
such as DNA, filamentous actin, lipids, and proteoglycans. Together these contribute to 
mucus plugging within the CF lung (Rose & Voynow, 2006; Voynow & Rubin, 2009).  This 
also facilitates microbial colonisation with P. aeruginosa, Staphylococcus aureus, Burkholderia 
cepacia, Prevotella spp, Candida spp, and Aspergillus spp. One remarkable consequence of 
these events is an exaggerated influx of activated neutrophils into the lung. Due to the large 
numbers of infiltrating neutrophils higher than normal levels of neutrophil-derived reactive 
oxidant species and proteases are reached. The consequences of these events include (i) an 
imbalance in the lung’s redox balance which can be further exaggerated due to reduced 
glutathione levels (Roum et al., 1993) that together lead to oxidative damage, and (ii) an 
imbalance in the normal protease-antiprotease balance due to the combined effects of 
oxidative inactivation of the normal anti-protease defences and the presence not only of 
excess neutrophil-derived but also bacterial-derived proteases (Greene & McElvaney, 2009).  
Neutrophil elastase (NE) is the major protease released by neutrophils in the CF lung. It has 
significant effects (Kelly et al., 2008). Not only does it up regulate the expression of other 
proteases including metalloproteases and cysteinyl cathepsins (Geraghty et al., 2007), it can 
also inactivate certain serine antiproteases (elafin and SLPI) and abrogate their anti-
inflammatory and immunomodulatory properties (Kelly et al., 2008; Weldon et al., 2009).  In 
concert with proteinase-3, macrophage-derived metalloelastases and elastolytic proteases 
expressed by P. aeruginosa, NE can promote secretion of mucus and degrade surfactant 
proteins and antimicrobials. NE can also directly injure epithelial cells and reduce ciliary 
beat frequency, cleave haemoglobin, complement components and immunoglobulins and 
interfere with effective neutrophil killing of microbes (Kelly et al., 2008). NE also contributes 
not only to the intracellular killing of gram-negative bacteria by neutrophils but also, once 
released extracellularly, can play a role in bacterial killing by comprising a key component 
of neutrophil extracellular traps (NETs). NETs are involved in host defense (Brinkmann et 
al., 2004). They bind gram-positive and gram-negative bacteria and allow neutrophils to 
directly deliver high concentrations of serine proteases that degrade virulence factors and 
kill bacteria.  
The high protease milieu of the CF lung can also impact deleteriously on antimicrobial 
protein activity. Defensins, lactoferrin, LL-37 and SLPI are all susceptible to proteolytic 
degradation particularly by cysteinyl cathepsins (Bergsson et al., 2009). 
Pulmonary inflammation in CF is also mediated by proinflammatory molecules such as C5a, 
LTB4, ceramide, and the chemotactic tripeptide Proline-Glycine-Proline (Greene, 2010), 
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which together contribute to the highly proinflammatory milieu in the CF lung. 
Furthermore the CF lung is a TLR agonist-rich milieu, represented by microbial-derived 
factors (bacterial, viral and fungal) and neutrophil elastase (NE), respectively (Greene et al., 
2008). The chronic inflammatory phenotype evident in CF airway epithelial cells is likely 
due in large part to activation of TLRs (Greene et al., 2008). In the CF lung NE–induced 
activation of TLR signalling is mediated via EGFR ligand generation and EGFR activation 
(Bergin et al., 2008). 
Overall the CF lung is highly prone to exaggerated inflammation. Although it is a 
neutrophil-rich environment, neutrophil degranulation and killing activity are 
dysfunctional. With inadequate anti-inflammatory mechanisms due to oxidation and 
proteolytic inactivation, incomplete resolution of infection occurs, bacterial biofilms remain 
established and infective exacerbations induce more severe symptoms. In females with CF 
these events may be further complicated due to gender-specific effects mediated in part by 
the female sex hormone estrogen which will now be discussed.  
3. Present understanding  
Estrogen, the predominant female hormone is released from the ovaries and subsequently 
circulates bound to sex hormone binding globulin (SHBG). Free E2 interacts with its specific 
estrogen receptors (ERs) to affect human physiological responses. ERs are predominantly 
based in the cell cytoplasm however more recently, an association with the cell plasma 
membrane has been described (Levin, 2009).  The major ERs are ERǂ and ERǃ, which share 
structural similarities however can effect opposing responses based on tissue type and 
location (Weihua et al., 2003).  
Traditional effector mechanisms associated with ERs are genomic where the hormone 
following binding to its receptor within the cell cytoplasm shuttles as a complex into the cell 
nucleus to induce gene transcription of estrogen-responsive genes (Metivier et al., 2006). 
Membrane associated ERs however act through non-genomic pathways that are more rapid 
affecting protein kinases and mobilizing intracellular calcium stores (Morley et al., 1992; 
Pedram et al., 2006; Pietras & Szego, 1975; Pietras et al., 2005; Razandi et al., 2000, 2004). 
Genomic and non-genomic pathways may interact with one another resulting in 
modification of gene transcription as the end-event. 
ERs are distributed throughout the human body however proportions vary by organ 
system. In some settings, both receptors are expressed whereas in others one subtype 
predominates. For example, ERǂ is related to reproductive tissues, bone, liver and the 
kidney whilst ERǃ is more abundant in the colon, bladder and lung.  Its role in the lung, 
particularly one that is chronically inflammed is a subject of continuing research in the 
context of CF (Chotirmall et al., 2010). Emerging inflammatory, immune and microbiological 
data suggests a potential role for E2 in the cause and course of chronic inflammatory lung 
diseases such as CF.  
Over a monthly menstrual cycle, in vivo E2 concentrations fluctuate with highest levels 
preceding ovulation with the lowest around menstruation. In view of its physiological role, 
ability to fluctuate in concentration, coupled to its capability to modulate cellular functions, 
responses and gene expression in those containing estrogen response elements (EREs), E2 
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represents an attractive avenue for investigation in terms of the gender differences observed 
in CF disease.  
Our current understanding of the role that E2 plays within the female CF lung is driven by 
investigations focused on its effects upon the dysfunctional pulmonary innate immune system 
and specifically some of its key components as described above. One such component is the 
ASL which is already known to be compromised in the setting of CFTR dysfunction. Coakley 
et al  (Coakley et al., 2008) have recently shown that in the setting of E2 exposure ASL is further 
compromised by dehydration and an increased risk of infection and subsequent exacerbation 
during high circulating E2 states. Therefore the two-week period of a single menstrual cycle 
where E2 concentrations are highest represents a high risk time-frame of acquiring infection 
and promoting exacerbation (Coakley et al., 2008). To date however, this proposed 
relationship between E2 concentration, menstrual cycle phase and infective exacerbations is yet 
to be illustrated by in vivo study and represents a future direction for clinical research.  
We have added to the understanding of E2’s role within the innate immune system in CF by 
demonstrating that high circulating E2 states confer a TLR hyporesponsiveness to a range of 
bacterial agonists manifested by an inhibition of IL-8 release. We found that the mechanism by 
which this phenomenon occurs is through ERǃ-mediated upregulation of SLPI, an important 
anti-protease/anti-inflammatory described above that is widely expressed within the 
respiratory tract (Chotirmall et al., 2010). SLPI, in separate work has been shown to 
competitively inhibit NF-κB p-65 subunit binding to DNA inhibiting the transcription of NF-
κB regulated genes such as IL-8 (Taggart et al., 2005). It is also important to note that in the 
non-CF context NF-κB has long been described to affect E2 signaling pathways, for example 
within circulating monocytes or tissue macrophages E2 can block LPS-induced NF-κB activity 
(Ghisletti et al., 2005). As we have demonstrated E2 to have an anti-inflammatory role in the 
context of the female CF lung, we hypothesized that although an environment of chronic 
uncontrolled inflammation may be damaging over the course of lifelong disease, acute surges 
in inflammation particularly in the setting of an acute infection may in fact provide protection 
and play a crucial role in facilitating bacterial clearance. Our published data would suggest 
however that in CF females this acute inflammatory response to an infective exacerbation is 
blunted by the presence of circulating E2 and when taken together with the compromised ASL, 
high circulating E2 states create an environment prone to both acquisition of infection and a 
subsequently compromised response to it (Chotirmall et al., 2010). It is becoming clearer with 
studies such as those described that E2 plays an important role in some of the observed gender 
differences in CF disease probably in tandem with other factors influencing clinical outcomes. 
One important offshoot from our work illustrating the hyporesponsive state induced by E2 
exposure is in potentially elucidating why anti-inflammatory agents such as the leukotriene B4 
antagonist have been unsuccessful in clinical trial, in fact causing premature trial termination 
(trial registration: NCT00060801) owing to increased infection within the treatment arm 
(Schmitt-Grohe & Zielen, 2005). Despite this, it remains important to highlight that clinical 
benefit has been shown following use of high-dose Ibuprofen however mechanisms to explain 
these outcomes are still sought (Konstan et al., 1995). Notably, we detected ERǃ to be the 
predominant ER within the CF airway by use of bronchial brushings obtained via 
bronchoscopy (Chotirmall et al., 2010). An increased ERǃ expression is associated with 
oxidative stress and hypoxic conditions explaining why it probably predominates in the CF 
context (Chotirmall et al., 2010; Schneider et al., 2000).  
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Fig. 1. The effect of 17ǃ-estradiol (E2) within the female CF airway. (A) In states of low 
circulating E2 (luteal phase), a dehydrated airway surface liquid (ASL) overlies the CF 
female airway epithelium. Within the lumen, antimicrobials (pink) such as lactoferrin and 
neutrophil chemokines e.g. interleukin-8 (IL-8) are detected along-with potential 
Pseudomonas aeruginosa colonization. (B) During high circulating E2 states (follicular phase), 
(I) a further disadvantaged and diminished ASL (Coakley et al; 2008) coupled with (II) an 
inhibitory effect and consequent dearth of anti-microbial peptides (Wang et al; 2010) 
combine to create an ideal environment primed for infection and exacerbation (III). (IV) 
Following infection, a blunted response to microbial agonists occur resulting in diminished 
luminal IL-8 and a hypo-responsive immune state (Chotirmall et al; 2010). These factors (I-
IV) combine to confer an elevated risk of infection and subsequent exacerbation in the E2 
exposed CF airway. 
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More recent work additionally highlights a role for E2 in P. aeruginosa infection. Proposed 
mechanisms include an enhanced Th17 regulated inflammatory response and suppression 
of innate antibacterial defences including the anti-microbial peptide lactoferrin (Wang et al., 
2010). When assessed in unison, our work and others may provide an important mechanistic 
basis for some of the gender differences observed in CF disease. For instance, in CF, a 
dehydrated ASL overlies the female airway epithelium whilst within the lumen, 
antimicrobials and the neutrophil chemokines (e.g. IL-8, LTB4, C5a and Proline-Glycine-
Proline) may be detected along with P. aeruginosa colonization. During high circulating E2 
states (follicular phase of the menstrual cycle), a further disadvantaged and diminished ASL 
(Coakley et al., 2008) coupled with impaired antimicrobial defences (Wang et al., 2010) 
combine to create an ideal environment primed for infection and exacerbation. Following 
infection, a blunted response to microbial agonists occurs resulting in diminished luminal 
IL-8 and a hypo-responsive immune state due to up-regulation of SLPI (Chotirmall et al., 
2010). In tandem, these factors combine to confer an elevated risk of infection and 
subsequent exacerbation in the E2 exposed CF airway (Figure 1). The effect of E2 however on 
other antimicrobial peptides, proteases and anti-proteases within the pulmonary 
environment is yet to be fully established.  
An alternate but critical avenue to further address gender differences in CF is by 
investigating the relationship between E2 and microorganisms within the CF airway. The CF 
microbiome is complex and encompasses interplay between various bacteria, viruses and 
fungi that co-exist some to detrimental effect. Whether circulating hormones such as E2 may 
influence this organism-rich milieu is an area of ongoing investigation. Microbial 
endocrinology, an emerging field has begun to address some of these important questions. 
This particular area of research focuses upon examining the effect of hormones on 
microorganisms such as P. aeruginosa. Thus far, published work in the field has described 
the effects of hormones such as noradrenaline and norepinephrine upon microorganisms 
that impact upon their adhesion proteins among other virulence factors (Freestone et al., 
1999, 2008). Despite the crucial functions that E2 carries out in its eukaryotic host, its impact 
upon prokaryotes are less clearly understood. Whilst E2 mediates its effects in eukaryotes 
through its major receptors –ǂ and –ǃ, comparable structures have been sought within 
prokaryotes. Estrogen binding proteins have been identified in P. aeruginosa whilst 
Escherichia coli possesses enzymes with analogous homology to human ERs (Baker, 1989; 
Rowland et al., 1992; Sugarman et al., 1990). Additionally, it is known that P. aeruginosa 
actively breaks down E2 to its major metabolite estriol (E3) and whether such metabolites can 
impact upon microorganisms particularly in the CF context remains to be determined 
(Fishman et al., 1960). Importantly, certain fungi are capable of producing estrogenic-like 
substances termed myco-estrogens however, whether these have any relevance for 
pulmonary environment in CF remain undetermined.  
4. Future directions  
Our understanding of the role that E2 may potentially play within the female CF airway has 
exponentially grown. Studies performed to date have implicated the hormone as a potential 
explanation for the long-observed gender differences in CF disease. With such advances to 
our understanding come further avenues for future exploration.    
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One such avenue is the role of modifying the endogenous concentration of E2 to alleviate its 
detrimental effects. Use of the anti-estrogen agent Tamoxifen or the oral contraceptive pill 
(OCP) can achieve this albeit by differing mechanisms. Tamoxifen in vitro is able to re-
instate the ASL to its pre-E2 state confirming the importance of E2 in mediating its negative 
effect (Coakley et al., 2008). Use of the OCP to modulate endogenous E2 concentrations 
would be a preferred and safer option although no studies to date have examined use of the 
OCP in CF in terms of effects on ASL or infection frequency. Such studies will undoubtedly 
emerge in due course and may provide a valuable potential future therapeutic option for CF 
females.  
Although E2 in its most active form is the chosen compound for most studies to date, it must 
be considered that through its natural metabolic process that E2 is broken down into 
metabolites such as E3. Whether such metabolites have effects within the CF airway on 
immune, inflammatory or infectious consequences is another area for future focus. In terms 
of innate immunity, prior publications in the non-respiratory setting have shown that E2 has 
a major influence on antimicrobial peptides such as lactoferrin, elafin and SLPI (Fahey et al., 
2008). 
Whilst we have shown in our work that E2 up-regulates SLPI in CF bronchial epithelium, 
the effects of E2 on other anti-microbials have yet to be fully established (Chotirmall et al., 
2010). Furthermore, the functional consequence of E2 exposure on the various anti-microbial 
peptides has not been addressed. 
The complex effects of E2 on inflammation continue to be deciphered and consequently 
ERǃ agonists have emerged as anti-inflammatory candidates. The development of such a 
compound however remains a pharmacological challenge that the forthcoming decade 
should address. Other important estrogen-based chemical compounds include the 
estrogen dendrimer conjugate (EDC) that binds ERs but excludes them from accessing 
the cell nucleus and exerting genomic effects (Harrington et al., 2006). Future research 
utilizing compounds such as the EDC will evaluate the precise contributions of genomic 
versus non-genomic mechanisms in a variety of in vitro and vivo settings that will 
provide further insight into the mechanistic explanations for the gender disparities 
acknowledged.  
Finally, an exciting new development in CF therapeutics is targeting of the basic genetic 
defect by the use of channel potentiators such as VX-770 (Accurso et al., 2010). Whether E2 or 
gender appears to impact upon these emerging agents and their effects represents another 
exciting direction for both CF basic science and clinical research leading us into the next 
decade of CF care.   
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